Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

2.36
-0.0800-3.28%
Post-market: 2.36-0.0016-0.07%19:51 EST
Volume:204.69K
Turnover:486.49K
Market Cap:66.31M
PE:-1.00
High:2.42
Open:2.42
Low:2.35
Close:2.44
52wk High:6.01
52wk Low:1.15
Shares:28.10M
Float Shares:20.75M
Volume Ratio:0.43
T/O Rate:0.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3483
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-97.83%
PB:-2.57
PE(LYR):-1.00

Loading ...

Hope Therapeutics, Inc., an NRX Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (One-D) Depression Treatment in Partnership With Ampa Health

THOMSON REUTERS
·
Nov 10

NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Oct 30

NRX Pharmaceuticals Inc : Ascendiant Capital Markets Raises Target Price to $47 From $46

THOMSON REUTERS
·
Oct 30

HOPE Therapeutics Acquires Cohen & Associates and Appoints Dr. Rebecca Cohen as Medical Director

Reuters
·
Oct 24

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 21

Hope Therapeutics - Acquisition Expected to Be Accretive to Co's Revenue and Ebitda

THOMSON REUTERS
·
Oct 20

Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Inclusion of Cohen & Associates, Llc of Sarasota, Fl Into the Hope Network and Appointment of DR. Rebecca Cohen as Hope Medical Director

THOMSON REUTERS
·
Oct 20

Press Release: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

Dow Jones
·
Oct 20

NRx Pharmaceuticals (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

TIPRANKS
·
Oct 18

NRX Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 16

NRx Pharmaceuticals (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies

TIPRANKS
·
Oct 10

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

GlobeNewswire
·
Oct 06

NRX Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 01

NRx Pharmaceuticals (NASDAQ: NRXP) Re-files ANDA for Preservative-Free IV Ketamine KETAFREE(TM)

TIPRANKS
·
Oct 01

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 29

NRX Pharmaceuticals Inc - Re-Files Anda for Ketafree to FDA

THOMSON REUTERS
·
Sep 29

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

GlobeNewswire
·
Sep 29

NRX Pharmaceuticals Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

Reuters
·
Sep 26

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Sep 25

NRx receives notification from FDA that Suitability Petition has been granted

TIPRANKS
·
Sep 24